One-year overall survival exceeded 80% across all mismatch levels in the prospective, 268-patient ACCESS trial of mismatched unrelated donor hematopoietic cell transplantation using post-transplant cyclophosphamide. Survival reached 86% for 4–6/8 mismatches and 79% for 7/8 mismatches. Patient-reported quality of life and physical function returned to baseline by 12 months with no clinically meaningful differences between cohorts, while 68% of patients experienced at least one grade 2+ infection in the first year, concentrated early post-transplant.
The NMDP- and CIBMTR-led program is headlining the Tandem Meetings with clinical and survivorship data supporting broader use of mismatched unrelated donors under PTCy-based GVHD prophylaxis, including consistent relapse, non-relapse mortality, GVHD-free relapse-free survival, and moderate-to-severe chronic GVHD rates across mismatch strata. A complementary analysis detailing infection burden under standard-dose PTCy was selected among the top infectious diseases abstracts. In parallel, NMDP is advancing ACCELERATE, a multicenter trial comparing reduced-dose versus standard-dose PTCy in the mismatched setting, targeting enrollment of 358 patients at up to 60 U.S. centers with primary completion projected in 2028.
Strategically, these data sharpen a shift already underway in donor selection: time-to-donor and access are moving ahead of strict HLA matching when PTCy can level outcomes across mismatch. That recalibration directly addresses long-standing inequities in donor availability for patients from underrepresented ancestries and could reduce delays that erode transplant intent-to-treat. The tension is clear, however. PTCy’s immunosuppression appears to be the price of admission for these broader match thresholds, with infections now the dominant early complication signal even as GVHD remains the primary driver of long-term quality-of-life deficits. The development push is now bifurcating—optimize PTCy dosing and supportive care to blunt infections, and layer or substitute next-generation GVHD prevention strategies without sacrificing the access gains.
For transplant centers, the operational impact is immediate. Donor algorithms will lean more heavily on MMUD pathways, potentially shortening search timelines and shifting workload toward confirmatory typing and graft logistics. Sites will need to reinforce infection surveillance, antimicrobial stewardship, and early post-transplant monitoring capacity to manage the higher infectious burden typical of PTCy, with implications for staffing, pharmacy, and ID consult throughput. For sponsors and CROs, ACCESS sets a benchmark: trials in HCT prophylaxis, anti-infectives, or adjunctive cellular therapies now have a well-characterized comparator framework and a clear mandate to integrate longitudinal PROs. Registry operators and HLA labs may see increased volumes as MMUD searches become routine rather than exceptional. Payers will weigh converging outcomes across donor types against cost curves shaped by shorter searches but potentially higher early supportive care demand.
Next, watch ACCELERATE’s read on whether reduced-dose PTCy can preserve GVHD control while lowering infection density; a favorable signal would accelerate MMUD adoption and could prompt guideline revisions. Longer-term follow-up from ACCESS will be critical to confirm durability on chronic GVHD, late effects, and non-relapse mortality beyond 12 months. Comparative effectiveness versus haploidentical and cord blood pathways remains a live question for centers balancing throughput, cost, and complication profiles. Expect near-term practice updates to focus less on reordering the donor hierarchy and more on protocol standardization, infection prevention packages, and PRO-informed survivorship care—pragmatic steps that determine whether MMUD’s access advantage translates into reproducible outcomes outside high-volume programs.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
